Ipsen Outlines Future Strategies and Commitments at Annual General Meeting

Highlights from Ipsen's Annual General Meeting 2024

On May 28, 2024, Ipsen S.A., hosted its Annual General Meeting at the prestigious Salons de l'Hôtel des Arts et Métiers in Paris. The meeting was chaired by Mr. Marc de Garidel, leading the Board of Directors, and witnessed the presence of numerous board members and executive leadership team.

The shareholders were invited to vote on 17 resolutions proposed by the Board of Directors. A significant resolution among these was the approval of a dividend payment of €1.20 per share. Shareholders can expect this payment on June 3, 2024, with the ex-date being May 30, 2024.

Key Appointments and Renewals

During the meeting, essential decisions were made regarding key positions within the company. PricewaterhouseCoopers Audit was appointed as the statutory auditor responsible for certifying sustainability information. Additionally, the terms of office of Mr. Philippe Bonhomme, representing BEECH TREE S.A., and Mrs. Carol Xueref were extended for another four years.

Furthermore, the temporary appointment of Mr. Pascal Touchon as a director was ratified, allowing him to serve for the remaining term of his predecessor.

Focus on Governance and Activity

Mr. Marc de Garidel provided insights on the governance, activities, and committees of Ipsen's Board of Directors throughout the fiscal year 2023. He ensured shareholders were well-informed about the company's internal workings and strategic direction.

Mr. David Loew, Ipsen's Chief Executive Officer, and Mr. Aymeric Le Chatelier, the Group Chief Financial Officer, delivered a comprehensive overview of the company's strategy, climate commitments, financial performance in 2023, and upcoming financial goals for 2024.

Ipsen's Climate Commitments

One of the highlighted topics during the meeting was Ipsen's dedication to combating climate change. The company emphasized its various initiatives aimed at reducing carbon footprint and promoting sustainability within the pharmaceutical industry.

These initiatives align with global climate objectives and showcase Ipsen’s commitment to responsible corporate practices.

2023 Financial Performance

The financial performance for the year 2023 was thoroughly reviewed, showing a robust fiscal health. Ipsen's strong performance was highlighted by increased revenues and profitability, a testament to their effective strategies and market positioning.

This positive performance is anticipated to continue, with clear objectives set for sustained growth and shareholder value in the upcoming year.

Future Financial Goals for 2024

Looking ahead, Ipsen outlined its financial goals for 2024, focusing on innovation, market expansion, and enhancing shareholder value. The leadership team stressed the importance of adapting to market changes and investing in research and development to stay at the forefront of the pharmaceutical industry.

These goals are aimed at driving long-term success and solidifying Ipsen's position as a leading global biopharmaceutical company.

Access to Annual General Meeting Records

For those interested in more detailed information, the results of the votes and the webcast of the Annual General Meeting will soon be accessible on Ipsen's official website: www.ipsen.com.

This access ensures transparency and allows shareholders and stakeholders to stay updated on the company’s proceedings and decisions.